(Q38088747)

English

What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.

scientific article published on 15 June 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

0 references

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Jens Kuhle

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

0 references

publication date

15 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Expert Opinion on Medical Diagnostics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

393-410

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The epidemiology of multiple sclerosis in Europe.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Secondary progressive multiple sclerosis: current knowledge and future challenges

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Primary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Prognostic factors in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cigarette smoking and the progression of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Clinical prognostic factors in multiple sclerosis: a natural history review

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The basis of intra-blood-brain-barrier IgG synthesis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A study of oligoclonal band negative multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Human leukocyte antigen

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The prognostic significance of cerebrospinal fluid in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Antimyelin antibodies with no progression to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Lack of association between antimyelin antibodies and progression to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Elevated neurofilament levels in neurological diseases.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Acute axonal damage predicts clinical outcome in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Axonal degeneration and inflammation in acute optic neuritis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The clinical course of neuromyelitis optica (Devic's syndrome).

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Clinical, CSF, and MRI findings in Devic's neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Multiple sclerosis in the Japanese population

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Optic neuromyelitis syndrome in Brazilian patients

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Characterisation of the spectrum of demyelinating disease in Western Australia.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Pure optic-spinal form of multiple sclerosis in Japan

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The spectrum of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

NMO-IgG predicts the outcome of recurrent optic neuritis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Neuromyelitis optica and asian phenotype of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF biomarkers: pinpointing Alzheimer pathogenesis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Longitudinal changes of CSF biomarkers in memory clinic patients.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Target-specific PET probes for neurodegenerative disorders related to dementia

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Amyloid imaging using high-field magnetic resonance

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF neurofilament proteins in the differential diagnosis of dementia

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Prevalence of parkinsonian signs and associated mortality in a community population of older people

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A systematic review of prevalence and incidence studies of dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Consensus statement on the diagnosis of multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebellar presentation of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Multiple system atrophy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The structure of the tau haplotype in controls and in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The alien hand and related signs

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Olfaction in neurodegenerative disorder

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Predicting motor decline and disability in Parkinson disease: a systematic review

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Prognostic factors for the progression of Parkinson's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Survival in progressive supranuclear palsy and frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

α-Synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Cerebrospinal fluid Abeta42 levels in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Blood-based neurochemical diagnosis of vascular dementia: a pilot study.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Onset, natural history and outcome in idiopathic adult motor neuron disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Early symptom progression rate is related to ALS outcome: a prospective population-based study

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Survival of patients with amyotrophic lateral sclerosis in a population-based registry

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Serum and CSF immunological findings in ALS.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Axonal damage markers in cerebrospinal fluid are increased in ALS.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

CSF glial markers correlate with survival in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS).

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Biochemical markers in CSF of ALS patients

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Focused proteomics in post-mortem human spinal cord

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Alzheimer's disease: the amyloid cascade hypothesis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Excitatory amino acid neurotoxicity and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Multiple sclerosis: Geoepidemiology, genetics and the environment

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Kennedy's disease: a triplet repeat disorder or a motor neuron disease?

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Alterations in neurofilament protein(s) in human leprous nerves: morphology, immunohistochemistry and Western immunoblot correlative study.

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Aluminum induces neurofilament aggregation by stabilizing cross-bridging of phosphorylated c-terminal sidearms

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Identification of novel APP/Abeta isoforms in human cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Targeting Cdk5 activity in neuronal degeneration and regeneration

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

The secretases: enzymes with therapeutic potential in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

High CSF neurofilament heavy chain levels in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis?

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.592184

21 January 2018

Identifiers

10.1517/17530059.2011.592184

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23484626%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38088747&oldid=1511060545"